IA-WORKIVA
20.10.2021 14:02:05 CEST | Business Wire | Press release
Workiva Inc. (NYSE:WK), the company that simplifies complex work, announced the winners of the 2021 Workiva Partner of the Year Awards. The awards recognize partners that have leveraged their significant industry and solution-specific experience to help customers expand their use of the Workiva platform to drive transparency in reporting and compliance. Award recipients were recognized during the Company’s virtual Global Partner Summit , held October 18 & 19.
“Our partners are instrumental in deploying the Workiva platform as a critical component in digital transformations across global enterprises,” said Corey Wells, vice president of partnerships and alliances at Workiva. “It’s an honor to recognize this year’s winners for helping drive the innovation and collaboration that has made a lasting impact on our customers' business.”
2021 Partner of the Year Award Winners
- Global Partner of the Year - Deloitte
- Global Technology Partner of the Year - FloQast
- North American Advisory Partner of the Year - PwC US
- North American Mid-Market Advisory Partner of the Year - Clearview Group
- North American Emerging Partner of the Year - DHG
- EMEA Partner of the Year - PwC Germany
- EMEA Emerging Partner of the Year - Advance Tax Compliance
- APAC Partner of the Year - PwC Hong Kong , PwC Japan , and PwC Taiwan
- Partner Innovation Award Winner - F.H. Black
More about the 2021 Partner of the Year Award Winners
Advance Tax Compliance (ATC) delivers high-quality implementations and supports the Workiva sales team with new clients. ATC is also an active contributor to Workiva marketing events, client demos and the Workiva Marketplace.
Clearview Group * has been named the North American Mid-Market Advisory Partner of the Year two years in a row. Clearview Group has a masterful understanding of Workiva solutions and delivers a compelling value story. Clearview Group has grown with Workiva, from supporting integrated risk management to developing a comprehensive service line, delivering advisory and transformation services powered by collaboration across management reporting, and financial reporting as well.
Deloitte * has been named global partner of the year two years in a row. Deloitte collaborates globally with Workiva, introducing the company to new customers, identifying new use cases and supporting sales teams. Deloitte has been instrumental in communicating the value of the Workiva platform and helping global customers use innovative technology to help address complex business problems.
DHG , a top 20 public accounting, tax, and advisory firm, helped bring Workiva’s Global Statutory Reporting (GSR) and Environmental, Social, and Governance (ESG) offerings to market. DHG’s global teams work across EMEA and North America with Workiva to help joint customers, which include some of the largest companies in the world, navigate the complexities of GSR and ESG reporting.
F.H. Black * is a groundbreaking services partner that has elevated and extended the most technically advanced aspects of the Workiva platform. F.H. Black's innovative methodology and investment into collaborating with the Workiva product teams have helped tailor Workiva’s solutions for the public sector, specifically the development of Government Finance Officers Association (GFOA) compliant financial reports, budget books, Governmental Accounting Standards Board (GASB) 87 solutions and State-mandated solutions.
FloQast * has won the Global Technology Partner of the Year award two years in a row. FloQast continues to bring extreme value to Workiva and their joint customers with their accounting workflow automation solution. FloQast also invested in developing a direct API into the Workiva platform to provide joint customers increased visibility of the Close to Report process that spans the Finance, Accounting and Reporting teams.
PwC* has a dedicated alliance team with a depth of experience that helps strengthen Workiva's global position as a strategic platform for businesses. PwC collaborates with Workiva globally across all use cases and seeks opportunities to embed Workiva into PwC tech-enabled offerings. PwC continually invests and grows their Workiva-focused resources and is dedicated to accelerating the success of Workiva and their shared, global customers. PwC was recognized for three regional awards: North American Partner of the Year (PwC US), EMEA Partner of the Year (PwC Germany), and APAC Partner of the Year (PwC Hong Kong, PwC Japan, and PwC Taiwan).
*Denotes Workiva Marketplace Innovator. Marketplace Innovators played a crucial role in the launch of the Workiva Marketplace by contributing meaningful templates, services and content that were readily available for customers to add to their workspaces and use upon the launch of the marketplace in August, 2021.
About Workiva
Workiva Inc. (NYSE: WK) simplifies complex work for thousands of organizations worldwide. Customers trust Workiva’s open, intelligent and intuitive platform to connect data, documents and teams. The results: improved efficiency, greater transparency and less risk. Learn more at workiva.com .
Read the Workiva blog: www.workiva.com/blog
Follow Workiva on LinkedIn: www.linkedin.com/company/workiva
Like Workiva on Facebook: www.facebook.com/workiva/
Follow Workiva on Twitter: www.twitter.com/Workiva
Follow Workiva on Instagram: www.instagram.com/workivalife
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005117/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom